AlopeciaNCT03382184
Fractional Photothermolysis for Hair Follicle Induction
A study testing Fraxel Dual laser and Halo laser in people with Alopecia, run by University of California, Irvine at 1 site in United States.
Trial summary
This study is being done to evaluate the effects of fractional photothermolysis (known as laser resurfacing) using fractional laser for the induction of hair follicles via skin rejuvenation in subjects with scalp alopecia (specifically, alopecia on the superior forehead at the frontal hairline). Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Alopecia
- What is being tested?
- Fraxel Dual laser and Halo laser
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Oct 2017to 29 May 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Must be between the ages of 18 to 90 years old
- Diagnosed with hair loss on scalp by a dermatology
- No other treatments for hair loss have been done in the past 1 month
- No evidence of spontaneous hair growth
- Good health
- Must agree to comply with study treatment and protocol
- Healthy scalp without evidence of neoplasm
- Scarring and/or non-scarring alopecia acceptable
Who cannot join
- Any visible signs of neoplasm, infection, inflammatory disease of the scalp
- No history of photosensitivity, impaired wound healing, chronic liver or kidney disease
- No concurrent use of minoxidil/Rogaine, platelet-rich plasma (PRP), or light devices for hair regrowth
- Has not initiated use of finasteride/Propecia or spironolactone in the 3 months preceding the study
Trial locations and contacts
1 site in 1 country.
United States1 site
University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center, Hewitt Hall
Irvine, California, 92697
About this study
Official title: Fractional Photothermolysis for the Induction of Hair Follicles Via Skin Rejuvenation
This study is being done to evaluate the effects of fractional photothermolysis (known as laser resurfacing) using fractional laser for the induction of hair follicles via skin rejuvenation in subjects with scalp alopecia (specifically, alopecia on the superior forehead at the frontal hairline). Fractional photothermolysis has been shown to be effective in promoting hair growth. The investigators will study 50 subjects who will be treated 6-10 times at 2-4 week intervals. Each participant will have half of their head treated with a laser, either Fraxel DUAL 1550 or Halo by Sciton, and the other half of their head will be left untreated as a control. Half of the individuals will randomly be assigned to the group to be treated with Fraxel DUAL 1550, and the other half will be treated with Halo by Sciton. Visual observation and digital, photographic, non-invasive imaging will be used to compare the treated and untreated area to assess for differences in hair follicle stimulation rates, number and density of hairs.
As noted above, the types of lasers we plan to use include the non-ablative fractional laser settings for the Fraxel DUAL 1550 and Halo by Sciton. A fractional laser is a laser that directs an intense burst of laser energy on the skin. The treatment deposits heat deep into the dermis to tighten skin and stimulate collagen remodeling. The necrotic (death of cells or tissue) injury heals rapidly and adverse effects are few. Laser resurfacing is commonly used for rejuvenation of the skin to improve quality, tone, and texture.
Read the detailed description
Introduction Alopecia is also known as hair loss, and it occurs due to aging, nutritional or hormonal imbalance, or immune system etiology. It affects both males and females of different ages and races. Hair may fall out in clumps, break off leaving short stubs, or become thinner over time. The alopecia can be of a scarring or non-scarring nature. The most common form of hair loss is non-scarring, or noncicatricial, alopecia. In this case, the damage is not permanent, and although hair loss cannot be cured, it can be treated. Hair loss is usually not a sign of an underlying medical disorder. However, hair loss may affect self-esteem and cause anxiety affecting the quality of life. Scarring, or cicatricial, alopecia is a rare disorder that destroys the hair follicle and replaces it with scar tissue, resulting in permanent hair loss.
Causes
There are many genes that contribute to hair loss, so it can be hereditary. There are also other causes, including:
- Thyroid disorders
- Pregnancy
- Anemia
- Autoimmune diseases like polycystic ovarian syndrome
- Skin conditions like Psoriasis and seborrheic dermatitis
Treatment Options Topical Minoxidil (Rogaine) and anti-inflammatory medications, such as topical and intra-lesional steroids, are used for alopecia. It is a solution that is applied directly to the scalp to stimulate the hair follicle. It slows hair loss, and some people grow new hair. Hair loss returns when the medication is stopped.
Finasteride is a prescription medicine that interferes with the production of a highly active form of testosterone that is linked to baldness. It slows hair loss. It works slightly better than minoxidil. Hair loss returns when you stop using the medicine. This prescription medication is also sometimes given to women who have been through menopause. Its role in female pattern hair loss is controversial, with both success and failure reported to occur.
Dutasteride is similar to finasteride, but may be more effective.
Hair transplants are also an option, though they are invasive and expensive. It consists of removing tiny plugs of hair from areas where the hair is continuing to grow and placing them in areas that are balding. This can cause minor scarring and possibly infection.
New Therapy Fractional photothermolysis was originally designed as a form of laser therapy to treat wrinkles and scars. Although the link between laser treatment and hair growth is not clear and the exact mechanism still unknown, there is evidence to support that laser irradiation holds potential for the induction of hair follicles in subjects with alopecia. Laser therapy has been reported to increase hair growth and activate hair follicles. The lasers rejuvenate skin, and hair follicles are a part of skin, along with nails, so through the rejuvenation of skin, these things also get rejuvenated. Clinical examples of photo-induced hair growth include the paradoxical hair growth after laser hair removal, and hair growth after some level of wound healing by lasers has been performed. Several studies have been performed, analyzing the effectiveness of laser treatment of different settings, and researchers have observed an increase in hair numbers and density on the treatment side of the head. Improvements were most notable when the laser settings followed a low energy and high density protocol. A review of the literature demonstrates that more research needs to be done on this topic, but fractional photothermolysis may be a new, effective way to treat different types of hair loss. The types of lasers the investigators plan to use include Fraxel restore and Sciton Halo, a fractional hybrid laser that combines fractional erbium ablative lasers with a fractional non-ablative laser. The use of the fractional photothermolysis Fraxel laser and Sciton Halo laser have been approved by the FDA for treatment of the hands, face, and body. Fraxel received aesthetic clearance in November 2003.
These lasers do not meet the definition of a significant risk device because the investigators do not believe that they present a potential for serious risk to the health, safety, or welfare of a subject. Side effects that have been reported from use with these lasers include redness and tenderness in the area that it was applied, and these side effects don't last more than a couple days. These lasers do not impair human health.
- Conditions
- Alopecia
- Being tested
- Fraxel Dual laser, Halo laser
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fraxel Dual laserDevice
The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.
Halo laserDevice
The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
| Study group | Role | What they receive |
|---|---|---|
| Fraxel DUAL 1550 nm | Experimental | The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth. 25 patients with alopecia will be part of this group. Receives: Device: Fraxel Dual laser |
| Halo Hybrid Laser 1550 nm | Experimental | The Halo laser will be used per protocol due to the dynamic thermal optimization technology for hair regrowth. 25 patients with alopecia will be part of this group. Receives: Device: Halo laser |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hair Density Change by as Seen by Dermoscopy
Hair density will be measured as increased or decreased before and after treatment using dermoscopy on both the treated and untreated scalp.
Measured: 24 weeks
Hair Density Change as Seen by Optical Coherence Tomography (OCT).
Hair density will be measured as increased or decreased before and after treatment using OCT on both the treated and untreated scalp.
Measured: 24 weeks
Secondary outcomes (1)
Hair Regrowth Impact on Quality of Life (Improved or Not Improved)
Patients will be asked how hair regrowth has affected their quality of life over the period of 12 weeks of treatment and then 12 weeks of follow-up using a Likert scale (1-5, worse to very much improved).
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Dec 2017
- Study start20 Oct 2017
- Primary completion29 May 2019
- Study completion29 May 2019
Why it stopped: The study procedures and enrollment were stopped due to COVID-19 restrictions on non-essential research. The study was not able to continue due to change in research personnel after research was able to resume.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for AlopeciaStudies of the same condition, open and under way.
- More trials run by University of California, IrvineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This is a prospective, dual-arm study involving the Fraxel DUAL or Halo laser for the regrowth of hair after alopecia.
- Masking
- None (open label)
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Irvine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Natasha Mesinkovska, University of California, Irvine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03382184
- Sponsor's protocol ID
- 20173385
- Status last verified
- Mar 2026
- First submitted
- 13 Dec 2017
- Last updated
- 3 Mar 2026
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: Currently there is no plan to share individual participant data with other researchers.
Publications
Kim WS, Lee HI, Lee JW, Lim YY, Lee SJ, Kim BJ, Kim MN, Song KY, Park WS. Fractional photothermolysis laser treatment of male pattern hair loss. Dermatol Surg. 2011 Jan;37(1):41-51. doi: 10.1111/j.1524-4725.2010.01833.x. Epub 2010 Dec 28.
PubMed 21199096Lee GY, Lee SJ, Kim WS. The effect of a 1550 nm fractional erbium-glass laser in female pattern hair loss. J Eur Acad Dermatol Venereol. 2011 Dec;25(12):1450-4. doi: 10.1111/j.1468-3083.2011.04183.x. Epub 2011 Aug 4.
PubMed 21812832Bae JM, Jung HM, Goo B, Park YM. Hair regrowth through wound healing process after ablative fractional laser treatment in a murine model. Lasers Surg Med. 2015 Jul;47(5):433-40. doi: 10.1002/lsm.22358. Epub 2015 May 6.
PubMed 25945952Update on fractional laser technology. J Clin Aesthet Dermatol. 2010 Jan;3(1):42-50. No abstract available.
PubMed 20725538Mlacker S, Aldahan AS, Simmons BJ, Shah V, McNamara CA, Samarkandy S, Nouri K. A review on laser and light-based therapies for alopecia areata. J Cosmet Laser Ther. 2017 Apr;19(2):93-99. doi: 10.1080/14764172.2016.1248440. Epub 2017 Jan 25.
PubMed 27802065Gupta AK, Carviel J, Abramovits W. Treating Alopecia Areata: Current Practices Versus New Directions. Am J Clin Dermatol. 2017 Feb;18(1):67-75. doi: 10.1007/s40257-016-0230-4.
PubMed 27770310
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fractional Photothermolysis for the Induction of Hair Follicles Via Skin Rejuvenation
- ClinicalTrials.gov ID
- NCT03382184
- Acronym / sponsor ID
- 20173385
- Conditions
- Alopecia
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The study procedures and enrollment were stopped due to COVID-19 restrictions on non-essential research. The study was not able to continue due to change in research personnel after research was able to resume.
- Enrolment
- 5 participants (actual)
- Lead sponsor
- University of California, IrvineUniversity, hospital or other
- Study start
- 20 Oct 2017 (actual)
- Primary completion
- 29 May 2019 (actual)
- Study completion
- 29 May 2019 (actual)
- First posted
- 22 Dec 2017 (actual)
- Results
- Posted 3 Mar 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to evaluate the effects of fractional photothermolysis (known as laser resurfacing) using fractional laser for the induction of hair follicles via skin rejuvenation in subjects with scalp alopecia (specifically, alopecia on the superior forehead at the frontal hairline). Fractional photothermolysis has been shown to be effective in promoting hair growth. The investigators will study 50 subjects who will be treated 6-10 times at 2-4 week intervals. Each participant will have half of their head treated with a laser, either Fraxel DUAL 1550 or Halo by Sciton, and the other half of their head will be left untreated as a control. Half of the individuals will randomly be assigned to the group to be treated with Fraxel DUAL 1550, and the other half will be treated with Halo by Sciton. Visual observation and digital, photographic, non-invasive imaging will be used to compare the treated and untreated area to assess for differences in hair follicle stimulation rates, number and density of hairs.
As noted above, the types of lasers we plan to use include the non-ablative fractional laser settings for the Fraxel DUAL 1550 and Halo by Sciton. A fractional laser is a laser that directs an intense burst of laser energy on the skin. The treatment deposits heat deep into the dermis to tighten skin and stimulate collagen remodeling. The necrotic (death of cells or tissue) injury heals rapidly and adverse effects are few. Laser resurfacing is commonly used for rejuvenation of the skin to improve quality, tone, and texture.
Detailed description
Introduction Alopecia is also known as hair loss, and it occurs due to aging, nutritional or hormonal imbalance, or immune system etiology. It affects both males and females of different ages and races. Hair may fall out in clumps, break off leaving short stubs, or become thinner over time. The alopecia can be of a scarring or non-scarring nature. The most common form of hair loss is non-scarring, or noncicatricial, alopecia. In this case, the damage is not permanent, and although hair loss cannot be cured, it can be treated. Hair loss is usually not a sign of an underlying medical disorder. However, hair loss may affect self-esteem and cause anxiety affecting the quality of life. Scarring, or cicatricial, alopecia is a rare disorder that destroys the hair follicle and replaces it with scar tissue, resulting in permanent hair loss.
Causes
There are many genes that contribute to hair loss, so it can be hereditary. There are also other causes, including:
- Thyroid disorders
- Pregnancy
- Anemia
- Autoimmune diseases like polycystic ovarian syndrome
- Skin conditions like Psoriasis and seborrheic dermatitis
Treatment Options Topical Minoxidil (Rogaine) and anti-inflammatory medications, such as topical and intra-lesional steroids, are used for alopecia. It is a solution that is applied directly to the scalp to stimulate the hair follicle. It slows hair loss, and some people grow new hair. Hair loss returns when the medication is stopped.
Finasteride is a prescription medicine that interferes with the production of a highly active form of testosterone that is linked to baldness. It slows hair loss. It works slightly better than minoxidil. Hair loss returns when you stop using the medicine. This prescription medication is also sometimes given to women who have been through menopause. Its role in female pattern hair loss is controversial, with both success and failure reported to occur.
Dutasteride is similar to finasteride, but may be more effective.
Hair transplants are also an option, though they are invasive and expensive. It consists of removing tiny plugs of hair from areas where the hair is continuing to grow and placing them in areas that are balding. This can cause minor scarring and possibly infection.
New Therapy Fractional photothermolysis was originally designed as a form of laser therapy to treat wrinkles and scars. Although the link between laser treatment and hair growth is not clear and the exact mechanism still unknown, there is evidence to support that laser irradiation holds potential for the induction of hair follicles in subjects with alopecia. Laser therapy has been reported to increase hair growth and activate hair follicles. The lasers rejuvenate skin, and hair follicles are a part of skin, along with nails, so through the rejuvenation of skin, these things also get rejuvenated. Clinical examples of photo-induced hair growth include the paradoxical hair growth after laser hair removal, and hair growth after some level of wound healing by lasers has been performed. Several studies have been performed, analyzing the effectiveness of laser treatment of different settings, and researchers have observed an increase in hair numbers and density on the treatment side of the head. Improvements were most notable when the laser settings followed a low energy and high density protocol. A review of the literature demonstrates that more research needs to be done on this topic, but fractional photothermolysis may be a new, effective way to treat different types of hair loss. The types of lasers the investigators plan to use include Fraxel restore and Sciton Halo, a fractional hybrid laser that combines fractional erbium ablative lasers with a fractional non-ablative laser. The use of the fractional photothermolysis Fraxel laser and Sciton Halo laser have been approved by the FDA for treatment of the hands, face, and body. Fraxel received aesthetic clearance in November 2003.
These lasers do not meet the definition of a significant risk device because the investigators do not believe that they present a potential for serious risk to the health, safety, or welfare of a subject. Side effects that have been reported from use with these lasers include redness and tenderness in the area that it was applied, and these side effects don't last more than a couple days. These lasers do not impair human health.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a prospective, dual-arm study involving the Fraxel DUAL or Halo laser for the regrowth of hair after alopecia.
| Arm | Type | Receives |
|---|---|---|
| Fraxel DUAL 1550 nm | Experimental | Device: Fraxel Dual laserThe Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth. 25 patients with alopecia will be part of this group. |
| Halo Hybrid Laser 1550 nm | Experimental | Device: Halo laserThe Halo laser will be used per protocol due to the dynamic thermal optimization technology for hair regrowth. 25 patients with alopecia will be part of this group. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Must be between the ages of 18 to 90 years old
- Diagnosed with hair loss on scalp by a dermatology
- No other treatments for hair loss have been done in the past 1 month
- No evidence of spontaneous hair growth
- Good health
Key exclusion criteria (4 listed)
- Any visible signs of neoplasm, infection, inflammatory disease of the scalp
- No history of photosensitivity, impaired wound healing, chronic liver or kidney disease
- No concurrent use of minoxidil/Rogaine, platelet-rich plasma (PRP), or light devices for hair regrowth
- Has not initiated use of finasteride/Propecia or spironolactone in the 3 months preceding the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fraxel Dual laserThe Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth. | Device | Fraxel DUAL 1550 nm |
| Halo laserThe Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth. | Device | Halo Hybrid Laser 1550 nm |
Primary outcome
Hair Density Change by as Seen by Dermoscopy
Time frame: 24 weeks
Hair density will be measured as increased or decreased before and after treatment using dermoscopy on both the treated and untreated scalp.
Hair Density Change as Seen by Optical Coherence Tomography (OCT).
Time frame: 24 weeks
Hair density will be measured as increased or decreased before and after treatment using OCT on both the treated and untreated scalp.
1 secondary outcome
Hair Regrowth Impact on Quality of Life (Improved or Not Improved)
Time frame: 24 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 21199096Kim WS, Lee HI, Lee JW, Lim YY, Lee SJ, Kim BJ, Kim MN, Song KY, Park WS. Fractional photothermolysis laser treatment of male pattern hair loss. Dermatol Surg. 2011 Jan;37(1):41-51. doi: 10.1111/j.1524-4725.2010.01833.x. Epub 2010 Dec 28.
- Background: PubMed 21812832Lee GY, Lee SJ, Kim WS. The effect of a 1550 nm fractional erbium-glass laser in female pattern hair loss. J Eur Acad Dermatol Venereol. 2011 Dec;25(12):1450-4. doi: 10.1111/j.1468-3083.2011.04183.x. Epub 2011 Aug 4.
- Background: PubMed 25945952Bae JM, Jung HM, Goo B, Park YM. Hair regrowth through wound healing process after ablative fractional laser treatment in a murine model. Lasers Surg Med. 2015 Jul;47(5):433-40. doi: 10.1002/lsm.22358. Epub 2015 May 6.
- Background: PubMed 20725538Update on fractional laser technology. J Clin Aesthet Dermatol. 2010 Jan;3(1):42-50. No abstract available.
- Background: PubMed 27802065Mlacker S, Aldahan AS, Simmons BJ, Shah V, McNamara CA, Samarkandy S, Nouri K. A review on laser and light-based therapies for alopecia areata. J Cosmet Laser Ther. 2017 Apr;19(2):93-99. doi: 10.1080/14764172.2016.1248440. Epub 2017 Jan 25.
- Background: PubMed 27770310Gupta AK, Carviel J, Abramovits W. Treating Alopecia Areata: Current Practices Versus New Directions. Am J Clin Dermatol. 2017 Feb;18(1):67-75. doi: 10.1007/s40257-016-0230-4.
- Individual participant dataSharing planned: No. Currently there is no plan to share individual participant data with other researchers.
Related trials for Alopecia
Active, not recruitingPhase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Active, not recruitingObservational study
Litfulo Capsules Special Investigation
Alopecia Areata
Active, not recruitingObservational study
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Alopecia Areata
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fraxel Dual laser and Halo laser in people with Alopecia, run by University of California, Irvine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 3 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hair Density Change by as Seen by Dermoscopy (time frame: 24 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03382184, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2026.